News articles about Encompass Health (NYSE:EHC) have been trending positive on Tuesday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Encompass Health earned a media sentiment score of 0.48 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.5303292247879 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- Brokerages Set $56.30 Target Price for Encompass Health Corp (EHC) (americanbankingnews.com)
- Encompass Health (EHC) vs. The Competition Head-To-Head Comparison (americanbankingnews.com)
- Encompass Health (EHC) Hits Fresh Highs: Is There Still Room to Run? (finance.yahoo.com)
- Zacks: Encompass Health Corp (EHC) Given Average Recommendation of “Buy” by Analysts (americanbankingnews.com)
- Financial Review: Encompass Health (EHC) versus Its Competitors (americanbankingnews.com)
EHC has been the topic of a number of research reports. ValuEngine raised shares of Encompass Health from a “hold” rating to a “buy” rating in a research note on Monday, February 5th. Craig Hallum reaffirmed a “buy” rating and issued a $60.00 price target (up from $54.00) on shares of Encompass Health in a research note on Tuesday, January 9th. Piper Jaffray Companies reissued a “hold” rating on shares of Encompass Health in a research note on Thursday, March 1st. Bank of America raised shares of Encompass Health from an “underperform” rating to a “neutral” rating in a research note on Thursday, January 4th. Finally, Credit Suisse Group reissued an “outperform” rating on shares of Encompass Health in a research note on Tuesday, February 27th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $60.00.
Encompass Health (NYSE:EHC) last released its earnings results on Monday, February 26th. The company reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.04. Encompass Health had a net margin of 6.45% and a return on equity of 20.59%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. sell-side analysts predict that Encompass Health will post 3.36 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Monday, April 2nd will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 1.71%. The ex-dividend date of this dividend is Thursday, March 29th. Encompass Health’s dividend payout ratio (DPR) is 37.31%.
COPYRIGHT VIOLATION NOTICE: “Encompass Health (EHC) Earns Media Sentiment Rating of 0.48” was reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2018/03/13/encompass-health-ehc-earns-media-sentiment-rating-of-0-48.html.
Encompass Health Company Profile
Encompass Health Corporation, formerly HealthSouth Corporation, is a provider of post-acute healthcare services, offering both facility-based and home-based post-acute services in 35 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies.
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.